David Meltzer to Life Expectancy
This is a "connection" page, showing publications David Meltzer has written about Life Expectancy.
Connection Strength
0.320
-
The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med. 2008 Jul 01; 149(1):11-9.
Score: 0.079
-
Variation in treatment preferences and care goals among older patients with diabetes and their physicians. Med Care. 2008 Mar; 46(3):275-86.
Score: 0.078
-
Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care. 2000 Jun; 38(6):679-85.
Score: 0.045
-
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat. 2015 Aug; 22(8):630-8.
Score: 0.032
-
Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis. Health Econ. 2016 Feb; 25(2):237-48.
Score: 0.031
-
Impact of delaying blood pressure control in patients with Type 2 diabetes: results of a decision analysis. J Gen Intern Med. 2012 Jun; 27(6):640-6.
Score: 0.025
-
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008 Apr; 46(4):349-56.
Score: 0.020
-
Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making. 1997 Oct-Dec; 17(4):382-9.
Score: 0.009